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Abstract The global consumption of opioids continues to rise, which has led to an increasing
rate of diversion, misuse, addiction, and deaths related to prescription opioids. This has been
particularly well documented in the USA; however, opioid analgesic dependence (OAD) is an
increasing concern in Europe. More guidance is required for European healthcare professionals
in the prevention, detection, treatment and management of OAD. The first Opioid Analgesic
Dependence Education Nexus (OPEN) Mentor Meeting was held in Berlin in September 2014
to address this. An international Expert Panel, combining expertise in OAD from Australia,
USA and Europe, invited 16 European experts in the pain and addiction fields to develop a
best-practice approach to OAD that European practitioners can adopt. The outcomes from this
meeting are presented here and included are a set of shared strategies that may be universally
adopted by all healthcare professionals working with patients who use opioids.
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Opioid analgesics are prescribed for moderate-to-severe pain, with numerous opioids classified
by the World Health Organization as essential medicines in the treatment of pain; however,
opioid dependence can develop in vulnerable persons with ongoing administration of opioid
medications and, as a result, opioid analgesic dependence (OAD) has become a global
concern. In addition to those receiving legal opioid prescriptions for pain, other populations
develop OAD through independent misuse of opioids. OAD has social, psychological and
physical consequences for the patient; risks to others through medication misuse, diversion and
accidental exposure; and also places a financial burden on healthcare systems.
The incidence of OAD is particularly pronounced in the USA and Australia. Opioid
analgesics were involved in 43 % of all drug overdose deaths in the USA in 2010 (Jones et al.
2013) and were responsible for more than twice the number of deaths from heroin and cocaine
combined (Giraudon et al. 2013). In Australia, non-medical use of pharmaceutical opioids
doubled between 2007 and 2010 (Roxburgh et al. 2013); however, opioid analgesic consumption
is rapidly increasing outside of these countries (International Narcotics Control Board 2014).
Many European countries consume greater than 100 mg/capita morphine equivalence (Interna-
tional Narcotics Control Board 2014). Opioid analgesics are regarded by international health
experts as the gold standard for relieving moderate-to-severe acute pain and some persistent pain
(Joranson et al. 2010). However, there is a need to balance access to prescription opioids with
prevention of dependence and other harms. Yet, in the USA, prescription opioid overdoses and
treatment admission for opioid dependence have increased in line with increased access to opioid
analgesics (Paulozzi et al. 2011). An association between higher dosing schedules in pain
treatment and opioid overdoses has been demonstrated (Bohnert et al. 2011), and overdoses
may occur as a result of misuse of diverted opioids. A recent review of opioid prescription data
across several European countries revealed that there are an estimated 22.8 million patients using
prescription opioid analgesics, with an estimated 455,000 likely to be dependent (Alho 2013). As
access to opioid analgesics continues to increase across Europe (International Narcotics Control
Board 2014) (Fig. 1), there is a growing need to provide education to both doctors and patients to


































Fig. 1 Opioid consumption in Europe is increasing. This graph illustrates the increase in opioid consumption in
European countries, following a similar trend in increases that has been seen in Australia. Data from the
International Narcotics Control Board. United Nations population data. Available at: https://ppsg.medicine.
wisc.edu/chart [Last accessed 6 October 2014]. *Morphine equivalence (ME) allows for equianalgesic compar-
isons between countries of the aggregate consumption of six principal opioids (fentanyl, hydromorphone,
methadone, morphine, oxycodone, and pethidine)
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Treatment of OAD is complicated by the frequent persistence of comorbid pain, which can
yield a variety of sub-populations that respond best to different treatment strategies. Interest-
ingly, some pain patients receive dose escalations without concomitant relief from pain and
actually experience greater pain-relief from opioid withdrawal (Krumova et al. 2013). Current-
ly, more guidance is required for healthcare professionals in Europe on the prevention,
detection, treatment and management of prescription OAD. The Opioid Analgesic Dependence
Education Nexus (OPEN) was created to meet this need by providing education to practitioners
and also to raise awareness of OAD in Europe. As American and Australian experts in the fields
of pain and addiction, with extensive experience of OAD, combined with the support of a
leading European pain expert with the knowledge of the European OAD landscape, we
convened in order to form a consensus for best practice in the prevention, detection, manage-
ment and treatment of OAD and to create a comprehensive educational toolkit that could be
shared amongst practitioners across Europe to provide guidance to healthcare professionals.
Methods
The Opioid Analgesic Dependence Education Nexus (OPEN) Mentor Meeting 2014
The Opioid Analgesic Dependence Education Nexus (OPEN)Mentor Meeting 2014 was held in
Berlin on 18–19 September 2014. The meeting content was created by the international Expert
Panel: Associate Professor Nicholas Lintzeris, Director of Drug and Alcohol Services, Australia;
Professor Seddon Savage, Adjunct Associate Professor of Anaesthesiology, USA; Professor
Mark Kraus, General Internist, USA; and Professor Christoph Maier, Endowed Chair in Pain
Management, Germany. Experts from across Europe were selected to attend the meeting based
on their clinical and scientific expertise in OAD and their reputation as a key opinion leader at an
international or national level; a strong publication record was also desirable. In total, 16
European experts attended the meeting: 7 from the UK, 3 from Germany and 6 from France.
There were 2 pain specialists, 13 addiction specialists and 1 pain and addiction specialist.
OPEN Mentor Survey
The 16 European experts were invited to complete a survey during the meeting that was
designed by the Expert Panel to assess the European experts’ views of OAD in Europe; current
unmet needs in the field; and recommended strategies for the prevention, detection, treatment
and management of OAD. The survey was completed independently and anonymously, and
results were collected from 13 experts.
Shared Strategies
The Expert Panel convened for three meetings to develop a consensus and propose a set of shared
strategies to be used as guidance for healthcare professionals in the prevention, treatment and
management of OAD. At the OPEN meeting in Berlin, the 16 European experts were invited to
indicate their support for the strategies through an anonymous and independent vote. The experts
were asked the extent to which they agreed that the proposed strategies would provide useful
guidance and be applicable to the prevention, detection, treatment and management of OAD in
Europe. Answers were given on a 4-point Likert Scale from ‘strongly agree’ to ‘strongly disagree’.
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The strategies were placed at stations and the experts invited to visit each station and contemplate
and discuss each strategy before completing a voting slip. 15 of the European experts took part in
this activity. The 15 experts voted on 8 of the 14 shared strategies; the remaining 6 strategies were
voted on by 12–14 of the experts. Logistical issues limited all experts from voting on all strategies.
Results
The Scale of the Problem in Europe – the European Expert Survey
We present here the results of a survey we developed in order to assess the OAD landscape in
Europe, including the scale of the problem, treatment strategies and challenges. Of the 16
European experts invited to complete the survey, 13 submitted responses.
& 100 % of the European experts surveyed believe that OAD is a priority problem in Europe
that needs special attention.
& 100 % of the European experts surveyed believe that OAD is increasing in the country in
which they practise (UK, France and Germany).
& 100 % of the European experts surveyed acknowledge the importance of diagnosing and
treating OAD.
– 69 % believe this to be very important.
– 31 % believe this to be important.
& 85 % of the European experts surveyed marked education of doctors and/or patients as a
key strategy for the prevention of OAD.
& The European experts most frequently reported codeine and tramadol as the opioids they
believe their patients are most commonly dependent upon.
& 100 % of the European experts surveyed acknowledged the importance of multidisciplin-
ary care, individualised treatment, involving patients in treatment decisions and designing
treatment that does not impede the patient’s ability to participate fully in their career or
educational activities (Table 1).
Table 1 European experts in pain and addiction endorse the following treatment approaches for OAD. The
experts ranked each approach on a 4-point Likert scale of 1–4, where 1 is ‘Not important’ and 4 is ‘Very
important’
Treatment approaches Mean score Level of importance No. votes
1 A multidisciplinary approach to care 3.69 Very important 13
2 Individualised treatment 3.85 Very important 13
3 Involved patients in treatment goals and decisions 3.92 Very important 13
4 Design treatment that does not impede the patient’s ability to
participate fully in their career or educational activities
3.77 Very important 13
5 Prescribe treatments that minimise the risk of misuse
and diversion
3.69 Very important 13
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Table 2 European experts in pain and addiction endorsed 14 shared strategies developed by an Expert Panel of
international experts that can be universally adopted for the prevention, detection, treatment and management of
OAD. Mentors ranked each strategy on a 4-point Likert Scale of 1–4 where 1 is ‘Strongly agree’ and 4 is
‘Strongly disagree’












1 OAD may result from a combination of
factors that should be taken into
account during all stages of patient
contact, including at the time of
prescribing pain medication, during
the detection of OAD and
throughout the treatment of OAD.
60.0 % 26.7 % 0.0 % 13.3 % 1.67 Agree 15
2 A comprehensive clinical assessment
should be performed on all patients
who may be considered to be
dependent on opioid analgesics. This
should include:
76.9 % 23.1 % 0.0 % 0.0 % 1.23 Strongly
agree
13
• a comprehensive assessment of the
patient’s substance use history
• a comprehensive assessment of the
patient’s mental health
• assessment of other health and social
issues
• a physical examination (current opioid
intoxication/withdrawal).
3 OAD patients who are no longer in
pain and recreational opioid
analgesic users should have
treatment that focuses on ad
dressing their dependence.
69.2 % 30.8 % 0.0 % 0.0 % 1.31 Strongly
agree
13
4 For OAD patients with co-existing
pain, treatment must address both
chronic conditions.
86.7 % 13.3 % 0.0 % 0.0 % 1.33 Strongly
agree
15
5 Treatment should be holistic and
manage pain (if applicable), opioid
dependence, social situations and
mental health, in addition to taking
into account complexities such as
age or comorbidities.
66.6 % 33.3 % 0.0 % 0.0 % 1.33 Strongly
agree
15
6 Prescribing should not be undertaken in
isolation. Healthcare professionals
should foster multidisciplinary
collaboration to achieve the best
possible outcomes for their patients.
66.6 % 33.3 % 0.0 % 0.0 % 1.33 Strongly
agree
15
7 Whether detoxification or maintenance
treatment is offered, psychosocial
services should be made available to
all patients; although, those who do
not take up the offer should not be
denied effective pharmacological
treatment.
64.3 % 35.7 % 0.0 % 0.0 % 1.36 Strongly
agree
14
8 When initiating maintenance treatment,
do not assume that the analgesic
being prescribed is what is being
taken – patients may be using more
or less than the amount prescribed or
61.5 % 38.5 % 0.0 % 0.0 % 1.38 Strongly
agree
13
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Regarding medication-assisted treatment for OAD, of the 11 European experts who
responded, 2 stated a preference to structure their patient’s treatment with their current opioid
Table 2 (continued)












administering their medication by
alternative methods.
9 When initiating maintenance treatment,
primary healthcare professionals
should consider specialist advice or
referral in the following
circumstances:
• Patients who have an unclear level
of opioid tolerance
• Patients who have high-risk polydrug
use
• Patients who use other medications
that may affect the metabolism of the
maintenance treatment
• Patients who have concomitant
physical conditions
• Patients who have severe concomitant
psychiatric conditions
• Patients who seek higher and more
rapid dose increases
• Patients who have difficulty
stabilising on a dose due to
continued substance use, side
effects or other complications.
46.7 % 53.3 % 0.0 % 0.0 % 1.53 Agree 15
10 Patient care should be mindful of the
stigmatisation that can be felt by
patients dependent on opioid
analgesics.
60.0 % 26.7 % 13.3 % 0.0 % 1.53 Agree 15
11 The impact that treatment may have on
the patient, for example on their
work and family commitments or the
management of their ongoing pain,
should be considered and the
treatment should be tailored
accordingly.
50 % 50 % 0.0 % 0.0 % 1.5 Strongly
agree
12
12 The treatment and management of
OAD patients should be
individualised based on ongoing
patient monitoring and assessment.
58.3 % 41.7 % 0.0 % 0.0 % 1.42 Strongly
agree
12
13 Patient reviews should occur frequently
(eg every week) early in treatment,
during periods of instability or
during withdrawal attempts. Stable
patients should be reviewed at least
once a month or when there is a
change in the patient’s
circumstances.
40.0 % 53.3 % 6.7 % 0.0 % 1.47 Strongly
agree
15
14 Measures should be taken to minimise
misuse and diversion of maintenance
medications.
60.0 % 40.0 % 0.0 % 0.0 % 1.40 Strongly
agree
15
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as a first-line treatment strategy. If this is not possible, one expert recommended
buprenorphine/naloxone and the other recommended either methadone or buprenorphine
depending on the patient’s need. The remaining 9 respondents listed buprenorphine or
buprenorphine/naloxone as their preferred treatment choice owing to the safety profile, low
stigma, efficacy and availability of the abuse deterrent formulation.
Shared Strategies for the Prevention, Detection, Treatment and Management
of OAD – the Expert Consensus
We developed 14 shared strategies, based on our international experience of OAD and
specialist experience in the pain and addiction fields, that we believe can be universally
adopted by practitioners for guidance in the prevention, detection, treatment and management
of OAD. The European experts reviewed and indicated their support for the shared strategies
by ranking their agreement with the strategies on a 4-point Likert Scale from ‘strongly agree’
to ‘strongly disagree’. The shared strategies gained unanimous support; following analysis of
the participants’ scoring, participants strongly agreed with 11 of the strategies and agreed with
the remaining 3 strategies (Table 2).
Conclusions
With a lack of centralised data collection and uncertainty regarding the rates of OAD, it is difficult
to estimate the scale of the problem in Europe arising from opioid analgesic dependence. We
created a survey and consensus process among European experts in pain and addiction in order to
assess the OAD landscape in Europe from a practitioner’s perspective, including the scale of the
problem, treatment strategies and challenges. Notably, all of the European experts surveyed
believe that OAD is a priority problem in Europe that needs special attention and that OAD is
increasing in the countries in which they practise (UK, France and Germany). These findings
should alert healthcare professionals across Europe to the growing problem of OAD and we, the
Expert Panel, together with the European experts agree that more education and guidance is
required in this field; the findings also need to be shared between primary care physicians, pain
specialists and addiction specialists to ensure that awareness, support and collaboration between
multiple service agencies can be focused on addressing this emerging problem.
Together with the European experts, we have agreed a series of shared strategies that we believe
can be universally adopted by practitioners for guidance in the prevention, detection, treatment and
management of OAD. By recommending these strategies in this publication, we hope to provide a
foundation for European guidance in OAD that can be shared among European practitioners. Of
the 14 shared strategies proposed, the European experts strongly agreed with 11 of the strategies
and agreed with the remaining 3. The following strategies gained the most support:
& A comprehensive clinical assessment should be performed on all patients who may be
considered to be dependent on opioid analgesics. This should include:
– a comprehensive assessment of the patient’s substance use history
– a comprehensive assessment of the patient’s mental health
– assessment of other health and social issues
– a physical examination (including evidence of current opioid intoxication/withdrawal).
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& OAD patients who are no longer in pain and recreational opioid analgesic users should
have treatment that focuses on addressing their dependence.
& For OAD patients with co-existing pain, treatment must address both chronic conditions.
& Treatment should be holistic and manage pain (if applicable), opioid dependence, social
situations and mental health, in addition to taking into account complexities such as age or
comorbidities.
& Prescribing should not be undertaken in isolation. Healthcare professionals should foster
multidisciplinary collaboration to achieve the best possible outcomes for their patients.
These strategies highlight the importance of multidisciplinary care and the utilisation of
additional expertise rather than practising in isolation and emphasise the need to manage all
aspects of a patient’s wellbeing. A comprehensive clinical assessment is key and should evaluate
the physical, psychological and social state of the patient. Should a patient be in intolerable
ongoing pain, it is necessary to ensure that the patient continues to be treated for their pain
alongside treatment for any dependence issues. In the course of this process, the European experts
also emphasised the importance of multidisciplinary care, individualised treatment, involving
patients in treatment decisions and designing treatments that do not impede the patient’s ability to
participate fully in their career or educational activities. The role of withdrawal from opioids in
patients experiencing problems with their opioid analgesics was also debated. Whilst a trial of
opioid withdrawal was considered to be warranted for many such patients, high rates of relapse to
opioid use in dependent patients (Kakko et al. 2003) highlights the importance of individualised
treatment plans and the need for flexibility in responding to patient outcomes. These recommen-
dations and strategies echo those recently introduced for management of pain in the 2014
Australian National Guidelines for Medication-Assisted Treatment of Opioid Dependence
(Gowing et al. 2014) and can be universally adopted by all healthcare professionals working
with patients who use opioids. Further education on OAD for European practitioners is required,
and this paper should form a basis for the development of more detailed guidelines that can be
used across healthcare disciplines to help manage those patients who become dependent on or
who are likely to become dependent on opioid analgesics in the European setting.
Limitations
Our experts and participants represent a limited number of developed countries: three Euro-
pean countries, the United States and Australia. The observations contained herein therefore
may not be generalisable to less developed countries or ones with highly different healthcare or
cultural structures. While there was high agreement on both observations related to OAD and
strategic approaches to addressing the problem across the countries surveyed, the limited
number of participants, with only pain and/or addiction medicine backgrounds, may not reflect
more diverse views within the countries represented. Finally, not all participants weighed in on
all questions or strategies, but because of widespread agreement among those who did
respond, we perceive that non-responses more likely reflect logistics rather than bias. None-
theless, we believe the process reflects a growing concern and suggests some reasonable
approaches to addressing the challenge.
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